/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Immutep Ltd

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.75 -0.0761(-7.61%) IMMP at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 1.67
Highest Today 1.78
Today’s Open 1.78
Prev. Close 1.84
52 Week High 2.71
52 Week Low 1.32
Day’s Range: Low 1.67 High 1.78
52-Week Range: Low 1.32 High 2.71
1 day return -
1 Week return -14.35
1 month return -2.8
3 month return +7.45
6 month return -4.41
1 year return -10.82
3 year return -24.12
5 year return -15.19
10 year return -

Institutional Holdings

BlackRock Inc 0.41

iShares Biotechnology ETF 0.39

Meridian Wealth Management, LLC 0.25

Sender Co & Partners, Inc. 0.08

Morgan Stanley - Brokerage Accounts 0.08

UBS Group AG 0.04

Steward Partners Investment Advisory, LLC 0.04

Susquehanna International Group, LLP 0.04

Dimensional Fund Advisors, Inc. 0.03

Verition Fund Managegment, LLC 0.03

LPL Financial Corp 0.02

Rhumbline Advisers 0.02

FNY Investment Advisers, LLC 0.01

Fidelity Nasdaq Composite Index 0.01

Geode Capital Management, LLC 0.01

XTX Topco Ltd 0.01

Bank of America Corp 0.01

Brighthouse/Dimensional Intl Sm Cm A 0.01

HighTower Advisors, LLC 0.01

DFA International Small Company I 0.00

DFA International Core Equity 2 I 0.00

DFA International Core Equity Class F 0.00

LVIP Dimensional Intl Core Eq Std 0.00

DFA Intl Sustainability Core 1 0.00

Tower Research Capital LLC 0.00

Dimensional Global Small Coms USD Acc 0.00

Royal Bank of Canada 0.00

DFA Asia Pacific Small Company I 0.00

GAMMA Investing LLC 0.00

DFA Global Small Company Institutional 0.00

SIMPLEX TRADING, LLC 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 270.83 M

PB Ratio 3.0817

PE Ratio 0.0

Enterprise Value 200.55 M

Total Assets 156.98 M

Volume 168030

Company Financials

Annual Revenue FY25:5043774 5.0M, FY24:3841877 3.8M, FY23:170369 0.2M, FY22:170369 0.2M, FY21:3968133 4.0M

Annual Profit FY25:-56366759 -56.4M, FY24:-37704847 -37.7M, FY23:null 0.0M, FY22:170369 0.2M, FY21:3968133 4.0M

Annual Net worth FY25:-61434165 -61.4M, FY24:-42716625 -42.7M, FY23:-39896348 -39.9M, FY22:-32210826 -32.2M, FY21:-29902624 -29.9M

Quarterly Revenue Q2/2025:1896103 1.9M, Q3/2024:1731134 1.7M, Q2/2024:1731134 1.7M, Q4/2023:2110743 2.1M, Q3/2023:1820188 1.8M

Quarterly Profit Q2/2025:-34183766 -34.2M, Q3/2024:-19379132 -19.4M, Q2/2024:-19379132 -19.4M, Q4/2023:1114955 1.1M, Q3/2023:896169 0.9M

Quarterly Net worth Q2/2025:-39056736 -39.1M, Q3/2024:-21488434 -21.5M, Q2/2024:-21488434 -21.5M, Q4/2023:-21228191 -21.2M, Q3/2023:-19273098 -19.3M

Fund house & investment objective

Company Information Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO Mr. Marc Voigt

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow